Boston Scientific Corporation (NYSE:BSX) ranks among the best medical stocks to buy according to analysts. On July 25, Truist Securities maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) while increasing its price target from $120 to $125. The price target upgrade comes after what Truist calls a \"strong quarter with multiple tailwinds supporting higher estimates.\" The firm noted that Boston Scientific Corporation (NYSE:BSX) produced a broad-based earnings beat, with its PFA and accelerated Watchman growth divisions showing excellent results. According to Truist, challenges in the TAVR (Transcatheter Aortic Valve Replacement) market should be more than compensated by Boston Scientific’s quarterly results, sustained momentum, and improved tariff outlook. In the second half of 2025, the firm expects \"beat and raises\" and stated confidence that Boston Scientific Corporation (NYSE:BSX) can continue to produce upside to its now-higher estimate. Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

Truist Boosts Boston Scientific (BSX) Price Target After Strong Quarter

Truist Securities raised its price target for Boston Scientific (BSX) from $120 to $125 after the company reported a strong quarter with earnings beats and growth in key divisions. The firm expects continued upside potential for BSX in 2025, though it notes AI stocks may offer higher returns.